Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptorum Group Ltd APM

Healthcare Biotechnology
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which... see more

Recent & Breaking News (NDAQ:APM)

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Business Wire April 30, 2024

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Business Wire March 6, 2024

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Business Wire December 22, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Business Wire December 21, 2023

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Business Wire November 16, 2023

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Business Wire August 10, 2023

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Business Wire June 22, 2023

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Business Wire June 9, 2023

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

Business Wire May 5, 2023

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Business Wire May 1, 2023

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Business Wire April 28, 2023

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Business Wire March 27, 2023

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire March 17, 2023

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Business Wire March 3, 2023

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Business Wire March 3, 2023

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Business Wire March 2, 2023

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Business Wire February 10, 2023

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Business Wire February 6, 2023

Aptorum Group Announces 1-for-10 Reverse Stock Split

Business Wire January 20, 2023

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Business Wire January 4, 2023